

Anacor Pharmaceuticals, Inc.
Form SC 13D/A
August 14, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

ANACOR PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$0.001 Par Value

(Title of Class of Securities)

032420 101

(CUSIP Number)

Victoria A. Whyte

GlaxoSmithKline plc

980 Great West Road

Brentford, Middlesex TW8 9GS

England

Telephone: +44 (0)208 047 5000

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

August 13, 2015

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 032420 101 SCHEDULE 13D/A3

Page 2 of 7

1. Names of Reporting Persons.

GlaxoSmithKline plc

2. Check the Appropriate Box if a Member of a Group

(a)

(b)

3. SEC Use Only

4. Source of Funds

WC

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

England and Wales

7. Sole Voting Power

2,171,374

Number of Shares 8. Shared Voting Power

Beneficially -0-

Owned by Each Reporting Person With: 9. Sole Dispositive Power

2,171,374

10. Shared Dispositive Power

-0-

11. Aggregate Amount Beneficially Owned by Each Reporting Person

2,171,374 (1)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares

13. Percent of Class Represented by Amount in Row (11)

4.9% (2)

14. Type of Reporting Person

CO

Footnotes:

(1) Shares of Common Stock held of record by GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of the Reporting Person.

(2) Based on 44,023,338 shares of Common Stock outstanding as of August 3, 2015.

ITEM 1. SECURITY AND ISSUER

This Amendment No. 3 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on December 10, 2010 (as amended by Amendment No. 1 filed on March 1, 2013 and Amendment No. 2 filed on February 13, 2015, the "Schedule 13D" and as amended by this Amendment No. 3, the "Statement"), with respect to the shares of common stock, par value \$0.001 per share (the "Common Stock"), of Anacor Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"). The Issuer's principal executive offices are located at 1020 East Meadow Circle, Palo Alto, CA 94303-4230. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

ITEM 2. IDENTITY AND BACKGROUND

The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 as attached to Amendment No. 1 in its entirety, and replacing it with Schedule 1 attached hereto.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

The responses set forth in Items 5(a), (c) and (e) of the Schedule 13D are hereby amended by deleting the previous responses to such Items in their entirety and replacing them with the following:

(a) The Reporting Person beneficially owns 2,171,374 shares of Common Stock, which represents 4.9% of the 44,023,338 shares of Common Stock outstanding as of August 3, 2015.

(c) On August 13, 2015, GlaxoSmithKline LLC, the record holder of the shares of Common Stock, sold an aggregate of 600,000 shares of Common Stock at a price per share (net of commissions) of \$135.95 in a privately negotiated transaction.

(e) The Reporting Person has ceased to be the beneficial owner of more than five percent of the Common Stock. Therefore, this is the final amendment to the Statement and an exit filing for the Reporting Person.

CUSIP No. 032420 101 SCHEDULE 13D/A3

Page 4 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: August 14, 2015

GLAXOSMITHKLINE PLC

/s/ Victoria A. Whyte

By: Victoria A. Whyte

Title: Company Secretary

CUSIP No. 032420 101 SCHEDULE 13D/A3

Page 5 of 7

Schedule I

Name	Business Address	Principal Occupation or Employment	Citizenship
Board of Directors			
Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Executive Officer	British
Simon Dingemans	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Financial Officer	British
Dr. Moncef Slaoui	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chairman Global Vaccines	Moroccan, Belgian & US
Sir Philip Hampton	980 Great West Road Brentford Middlesex, England TW8 9GS	Chairman and Company Director	British
Professor Sir Roy Anderson	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British
Dr. Stephanie Burns	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Stacey Cartwright	980 Great West Road Brentford	Company Director	British

Edgar Filing: Anacor Pharmaceuticals, Inc. - Form SC 13D/A

Middlesex, England
TW8 9GS

Judy Lewent	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Sir Deryck Maughan	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British

Dr. Daniel Podolsky	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director US
Lynn Elsenhans	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director US
Hans Wijers	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director Dutch
Urs Rohner	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director Swiss

**Corporate
Executive Team**

Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Executive Officer	British
Simon Dingemans	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Financial Officer	British
Dr. Moncef Slaoui	980 Great West Road Brentford Middlesex, England	Executive Director Chairman Global Vaccines	Moroccan, Belgian & US

TW8 9GS

CUSIP No. 032420 101 SCHEDULE 13D/A3

Page 7 of 7

	980 Great West Road		
Nick Hirons	Brentford Middlesex TW8 9GS	Senior Vice President, Global Ethics and Compliance	British
Abbas Hussain	150 Beach Road 22-00 Gateway West 189720 Singapore	President, Global Pharmaceuticals	British
David Redfern	980 Great West Road Brentford Middlesex, England TW8 9GS	Chief Strategy Officer	British
Claire Thomas	980 Great West Road Brentford Middlesex, England TW8 9GS	Senior Vice President, Human Resources	British
Philip Thomson	980 Great West Road Brentford Middlesex, England TW8 9GS	Senior Vice President, Communications and Government Affairs	British
Daniel Troy	The Navy Yard 5 Crescent Drive Philadelphia,	Senior Vice President & General Counsel	US

	PA 19112 980 Great West Road		
Dr. Patrick Vallance	Brentford Middlesex, England TW8 9GS 980 Great West Road	President, Pharmaceuticals R&D	British
Emma Walmsley	Brentford Middlesex, England TW8 9GS 980 Great West Road	Chief Executive Officer, GSK Consumer Healthcare	British
Roger Connor	Brentford Middlesex, England TW8 9GS	President, Global Manufacturing & Supply	Irish